Related Experiment Video
Updated: Aug 5, 2025
05:34
Isolation and Culturing of Primary Murine Adipocytes from Lean and Obese Mice
Published on: January 24, 2025
1.2K
Circulating Adiponectin Levels Are Inversely Associated with Mortality and Respiratory Failure in Patients
Bettina Hindsberger1, Birgitte Lindegaard2,3, Liv Rabøl Andersen1
1Center of Clinical Research and Disruption of Infectious Diseases (CREDID), Department of Infectious Diseases, Copenhagen University Hospital-Amager and Hvidovre, 2650 Hvidovre, Denmark.
International Journal of Endocrinology
|March 24, 2023
Summary
Higher adiponectin levels in COVID-19 patients were linked to reduced mortality and respiratory failure. Leptin levels showed no significant association with COVID-19 outcomes.
Area of Science:
- Endocrinology
- Infectious Diseases
- Immunology
Background:
- Chronic low-grade inflammation and dysregulated adipose tissue may worsen COVID-19.
- Adipose tissue-derived hormones (adipokines) may influence COVID-19 severity.
Purpose of the Study:
- To investigate the relationship between leptin and adiponectin levels and COVID-19 severity and mortality.
- To assess the prognostic value of adipokines in SARS-CoV-2 infection.
Main Methods:
- Serum leptin and adiponectin levels were measured in 123 COVID-19 patients.
- Logistic regression analysis was used to determine associations with 90-day mortality and respiratory failure.
- Adjustments were made for age, sex, BMI, and comorbidities.
Main Results:
- Adiponectin levels were inversely associated with mortality and respiratory failure.
- A doubling of adiponectin correlated with a 38% reduction in 90-day mortality odds (OR 0.62) and a 40% reduction in respiratory failure odds (OR 0.60).
- Leptin levels did not show a significant association with COVID-19 outcomes.
Conclusions:
- Circulating adiponectin at admission is a potential negative prognostic marker for COVID-19.
- Adiponectin's role in SARS-CoV-2 infection progression and prognosis warrants further investigation.
- Adipokines may represent therapeutic targets for managing severe COVID-19.
Related Concept Videos
01:29Acute Respiratory Failure-V
174
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
174
01:30Acute Respiratory Failure-III
240
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
240
01:23Acute Respiratory Failure-IV
184
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
184
01:21Acute Respiratory Failure-II
298
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
298
01:21Acute Respiratory Failure-I
262
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
262
01:20COPD: Pathogenesis and Clinical Features
394
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
394